Toothpaste aimed at treating chronic mouth sores in transplant patients shows early promise
NCT ID NCT06638879
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested a special toothpaste containing tacrolimus in 7 patients with oral chronic graft vs. host disease (cGVHD) after a stem cell transplant. Participants used the toothpaste twice daily for three months alongside their usual medications. The goal was to see if it could help manage painful mouth ulcers and gather information for future larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tacrolimus toothpaste
- What this could lead to
- If this works, it could offer a new topical option to manage painful mouth sores from chronic graft vs. host disease after a stem cell transplant.
- What could go wrong
- This is a very early Phase 1 study with only 7 participants, so results may not apply to everyone. It is not a cure and is meant only as an add-on to standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE ORAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States